

Lesson Learned from the OPEN CTO Trial

J. Aaron Grantham, MD, FACC

**Associate Professor of Medicine
University of Missouri Kansas City**



Saint Luke's

MID AMERICA HEART INSTITUTE

Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship


- Grant/Research Support
- Consulting Fees/Honoraria
- Major Stock Shareholder/Equity
- Royalty Income
- Ownership/Founder
- Intellectual Property Rights
- Employment/Director

Company

- Boston Scientific
- BSCI, ABT, Asahi-Intecc, Vascular Solutions, St Jude (Abbott)
- Corindus, Insysiv Inc.
- None
- CTOfundamentals.org
- None
- Corindus Vascular Robotics

The Hybrid Approach to CTO-PCI

- Systematic
- Adoption of four strategies
- Sequence based on probability of success
- Rapid decision making



The Hybrid Algorithm

Four things determine how many and which option to begin with

1. Proximal Cap Anatomy

- Defined or Ambiguous?

2. Target

- Favorable for reentry?

3. Collaterals

- Useable or not?

4. Occlusion length

- <20mm or \geq 20mm?


Direction

Crossing strategy


OPEN CTO Design

Design

- **DESIGN:** Prospective, non-randomized, single-arm, multi-center clinical evaluation of the Hybrid CTO-PCI
- **OBJECTIVE:** To evaluate the Success, safety, efficiency, appropriateness, health status outcomes, and costs of CTO-PCI
- **PRINCIPAL INVESTIGATOR**
- J. Aaron Grantham, MD, FACC
Saint Luke's Mid America Heart Institute, Kansas City, Mo. USA



OPEN CTO Sites



Rigor Used in OPEN CTO

- **Auditing through NCDR**
 - Truly consecutive, unselected, fully reported
- **Angiographic core lab analysis**
 - Unbiased QCA
- **Centralized call center follow up (96%)**
- **CEC adjudication**
- **Broad spectrum of operators using a single methodological approach**

Audit Results

Table 1 The NCDR audit results

| | Total in NCDR (n = 1096) [n (%)] | Enrolled (n = 987) [n (%)] | Not enrolled (n = 109) [n (%)] | P-value |
|--------------------------------------|-------------------------------------|-------------------------------|-----------------------------------|-------------------|
| Patient characteristics | | | | |
| Age (years) | 65.3 ± 10.3 | 65.3 ± 10.3 | 65.2 ± 10.4 | 0.893 |
| Male | 883 (80.6) | 797 (80.7) | 86 (78.9) | 0.643 |
| Race White | 988 (90.1) | 903 (91.5) | 85 (78.0) | < 0.001 |
| Hispanic origin | 40 (3.7) | 31 (3.2) | 9 (8.4) | 0.012 |
| Smoker | 188 (17.2) | 167 (16.9) | 21 (19.3) | 0.537 |
| Hypertension | 975 (89.0) | 884 (89.6) | 91 (83.5) | 0.054 |
| Dyslipidemia | 1030 (94.1) | 928 (94.1) | 102 (93.6) | 0.820 |
| Previous MI | 535 (48.8) | 479 (48.5) | 56 (51.4) | 0.572 |
| Previous CHF | 242 (22.1) | 215 (21.8) | 27 (24.8) | 0.475 |
| Previous PCI | 728 (66.4) | 657 (66.6) | 71 (65.1) | 0.764 |
| Previous CABG | 389 (35.5) | 358 (36.3) | 31 (28.4) | 0.103 |
| CKD stage 4 | 27 (2.5) | 25 (2.5) | 2 (1.8) | 1.000 |
| Diabetes | 442 (40.3) | 403 (40.8) | 39 (35.8) | 0.307 |
| Chronic lung disease | 144 (13.1) | 131 (13.3) | 13 (11.9) | 0.693 |
| Procedural outcomes | | | | |
| Technical success by NCDR definition | 981 (89.5) | 888 (90.0) | 93 (85.3) | 0.132 |


Baseline Patient and Lesion Characteristics in OPEN CTO

| Patient Characteristic | |
|-----------------------------|-------------|
| Age (yrs) | 65.4 ± 10.3 |
| Male sex (%) | 80.2% |
| BMI (Kg/m ² BSA) | 30.8 ± 9.1 |
| Heart Rate (bpm) | 68.5 ± 12.8 |
| Smoking (ever) | 64.5% |
| Diabetes(%) | 41.4% |
| Hypertension(%) | 86.9% |
| Prior MI(%) | 48.4% |
| Prior CABG(%) | 36.9% |
| Prior PCI(%) | 66.0% |
| Prior CHF(%) | 22.6% |
| PAD(%) | 17.4% |
| CKD>stage 1(%) | 13.3% |
| EF (%) | 51.1 ± 13.7 |


| Angiographic Characteristic | |
|-----------------------------|-------------|
| CTO only (%) | 86.2 |
| Complete Revasc (%) | 82.3 |
| Target Vessel RCA (%) | 60.5 |
| LAD (%) | 19.6 |
| LCX (%) | 13.3 |
| Occlusion Length (mm) | 29.9 ± 24.3 |
| Length>20 mm (%) | 54.8 |
| Total lesion length (mm) | 63.4 ± 28.6 |
| JCTO score <3 (%) | 81.2 |
| JCTO score ≥3 (%) | 19.7 |

Indications and Appropriateness

Primary Indication



Appropriateness



Procedural Results in OPEN CTO



*89% operator reported
86% core lab adjudicated*



119 ± 72 min




2.5 ± 1.9 Gy



265 ± 194 ml


Hybrid Algorithm Use

First Strategy N=1000



Success rate 58%

Second Strategy N=420



Success rate 55%

Deaths and Adverse Events

Riley and McCabe

| Patient | In Hosp | Perforation | Periproc MI | Post CABG |
|---------|---------|-------------|-------------|-----------|
| 1 | Yes | Yes | Yes | Yes ← |
| 2 | Yes | Yes | Yes | No |
| 3 | Yes | Yes | No | No |
| 4 | Yes | Yes | No | Yes ← |
| 5 | Yes | Yes | No | No |
| 6 | Yes | Yes | No | No |
| 7 | Yes | Yes | No | Yes ← |
| 8 | Yes | Yes | No | Yes ← |
| 9 | Yes | Yes | No | Yes ← |

All 9 deaths were associated with a complication


5/9 deaths associated with perforation were in post CABG patients

Unpublished Data from OPEN CTO


Procedural Mortality In Context

- **0.9% (95% CI 0.6-1.2%)**
 - Mortality in NCDR registry 0.65%
 - Expected mortality by NCDR risk model 0.41%
 - Expected mortality of surgery from STS risk calculator 1.67%
 - Mortality associated with SVG PCI 1.1%


Predictors of MACCE




12 Month Mortality Success vs Failure




12 Month all Cause Rehospitalization




12 Month all Cause Unplanned Rehospitalization



12 Month TVR




Outcomes After Single Vessel CTO PCI




Appropriateness and Outcomes


SAQ Angina Frequency




SAQ Summary Score




SAQ AF




SAQ QoL




Adjusted Between Group Differences in Early HS Response to CTO PCI




One Year Health Status Changes



Rose Dyspnea Score



PHQ-8 Scores



Conclusions

- **The early health status benefits of CTO PCI success vs failure are attenuated over time**
- **Primarily due to catch up among initially failed procedures**
- **Mechanisms might include reattempts, facilitated recanalization, med changes, accommodation, regression to the mean, or placebo effect**
- **Patients with appropriate indications gain the most in QoL, but rarely appropriate may benefit**
- **Clinical event rates (death, MI, TVR, rehospitalization) are similar among success and failed groups**